N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
N/A N=52 Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals
Obesity · Overweight
Primary: Change in Interleukin-6 (Value at Week 8 Minus Value at Week 0) — 0.35; -1.08; 0.51 pg/mL — p=0.9942
N/A N=22 Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
N/A N=21 Psoriasis Inflammation and Systemic Co Morbidities
Psoriasis
Primary: Change in Histology
N/A N=74 Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Primary: Coronary Flow Reserve — 2.65 ratio
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
Phase 2 N=45 Targeting Inflammation to Treat Cardiovascular Aging
Vascular Stiffness · Endothelial Dysfunction · Diastolic Dysfunction
Primary: Carotid-femoral Pulse Wave Velocity (CFPWV) — 831.3; 785.1; 538.0; 839.6 cm/sec
N/A N=23 Watermelon Focused Dietary Inflammatory Index Intervention
Inflammation · Diet Modification
Primary: Change in C-reactive Protein — -0.04; -0.56 mg/L
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 3 N=123 Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Vascular Inflammation · Atherosclerotic Cardiovascular Disease
Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change
N/A N=46 Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
Dysbiosis · Endotoxemia · Metabolic Syndrome
Primary: Serum Endotoxin — 31.6; 26.7; 44.5; 39.1 EU/mL
Phase 2 N=36 Effects of rhLactoferrin on Chronic Inflammation in the Elderly
Inflammation · Cognitive Deterioration
Primary: The Effect of Rhlactoferrin on Serum Levels of Interleukin-6 (IL-6) — -0.640; 0.932 Percent change of IL-6
N/A N=114 Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
Phase 2 N=9 Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
Type 2 Diabetes Mellitus · Insulin Resistance
Primary: Insulin Sensitivity at 6 Months From Baseline — 9.9; 6.4 (mL/kg/min)/(microIU/mL) — p=<0.05
Phase 2 N=25 Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction
Polycystic Ovary Syndrome
Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004
N/A N=4 Dietary Soy Isoflavones In Chronic Pancreatitis
Chronic Pancreatitis
Primary: Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 4 N=54 The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
Type 2 Diabetes · Diabetes
Primary: Change in Fasting Plasma Glucose Concentration — 4.7; 0.0 mmol/l
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Phase 4 N=29 Fish Oils and Adipose Inflammation Reduction
Obesity
Primary: Change in Plasma Fractalkine Levels — 0.42; 0.46; 0.48; 0.45 ng/ml
N/A N=10 Anti-inflammatory Effects of the Fiber
Type 2 Diabetes
Primary: Peak Change in From Baseline in Reactive Oxygen Species (ROS) Generation — 224; 167 percentage of change
N/A N=15 Human Biological Responses to Low Level Ozone
Environmental Exposure · Nasal Inflammation
Primary: Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid Immediately Post-Exposure From Baseline — -1.02; -6.8 percent PMNs in nasal lavage fluid
Phase 4 N=280 Anti-inflammatory Effects of Colchicine in PCI
Coronary Artery Disease
Primary: Percent Change in Post-procedural IL-6 Concentration From Baseline to 30 Min -1 hr After PCI — 0; 20 % change — p=0.31
Phase 3 N=251 Targeting Inflammation Using Salsalate in CardioVascular Disease
Coronary Artery Disease · Overweight
Primary: Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months — 0; 0 mm^3
Phase 3 N=20 Sitagliptin Therapy and Kinetics of Inflammatory Markers
Type 2 Diabetes Mellitus
Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period
N/A N=60 Leukocyte Function in Asthma and COPD
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
Phase 2 N=12 Blood Lipopolysaccharide (LPS) Rifaximin Study
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
Phase 3 N=402 Sub-clinical Inflammation and Iron Supplementation
Anemia
Primary: Haemoglobin Level — 88.3; 89.2; 88.4; 89.6 g/L — p=<0.05